Navigation Links
As Healthcare Spending is Predicted to Exceed 4 Trillion in Less Than 10 Years, Technology will be Called upon to Stem the Tide
Date:2/28/2008

tements that reflect the Company's current expectations regarding future events. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties. Actual results may differ significantly from projected results due to a number of factors, including, but not limited to assumptions, beliefs and opinions relating to the business and growth strategy of VirtualHealth Technologies, Inc. and its wholly owned subsidiaries Verified Prescription Safeguards, Inc., VPS Holding, LLC, Envoii Healthcare, LLC, Medical Office Software, Inc. and implementation thereof, based upon the Company's interpretation and analysis of financial and market conditions, the decisions of businesses with whom the Company is either engaged in business with or negotiating, healthcare industry trends and management's ability to successfully finance, develop, market, sell and implement its e-commerce and internet solutions, clinical and financial e-transaction services and software applications to physicians, pharmacies, governmental agencies, laboratories, insurance companies, HMOs, and payers. These factors and other risk factors are more fully discussed in the Company's filings with the Securities and Exchange Commission. The Company expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE VirtualHealth Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults
2. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
3. Healthcare Businesswomens Association Names Genentechs Leonard Kanavy, Vice President, Commercial Operations as the 2008 Honorable Mentor
4. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
5. APIC Selected as Faculty in Blue Shield of California Foundation Initiative to Fight Healthcare-Associated Infections
6. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
7. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
8. AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance
9. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
10. Agfa HealthCare, InterComponentWare, and Sun Microsystems Join Open eHealth Foundation at HIMSS08
11. Microsoft and Microsoft Healthcare Users Group Announce Winners of MS-HUG Healthcare Innovation Awards 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ALE, N.J., Nov. 21 Barr ...ed that its shareholders overwhelmingly approved t...uisition of Barr by Teva Pharmaceuticals Industrie...e demonstrated the overwhelming support of the tra...Downey, Barr,s Chairman and CEO. "We are pleased w...
(Date:11/21/2008)...430 B.C., a new and deadly diseaseits cause remain...y-state was teeming with citizens, soldiers and re...parta. As streets filled with corpses, social orde...ss returned twice and Athens lost a third of its p...ns marked the beginning of the end of the Golden A...
(Date:11/21/2008)...OCHELLE, N.Y., Nov. 21 A prestigio...are providers will gather in Williamsburg, VA on M...n practical, clinical information on cutting-edge ..., and innovative research advances that impact pat...n, and registration information is available at w...
(Date:11/21/2008)...EW YORK Tobacco use is more prevalent and smoki...ion Deficit Hyperactivity Disorder (A.D.H.D.) In ...ractivity symptoms, those who exhibited elevated h...tention, showed lower quit rates after 8 weeks tha...ithout the A.D.H.D. symptoms. The study, now avai...
Breaking Medicine News(10 mins):Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find 2
...Complication as its other name. Among the many com... would be the foot ulcer, as damage can be severe ...his dreaded foot ulcer, a boon in disguise would b...age electric current to the skin. //Such an electr...
...sease as so much of research are going on in ident... ongoing research, hyperhomocysteinemia (increased... be one of the risk factors.// Dr. O Mayer Jr and ...lsen, Czech Republic, found as a result of their s...
...ts as pets had developed a better immune system ag...to suppport the "hygiene"or "cleanliness" hypothes... bacteria or allergens keeps one branch of our imm...rom developing properly. As a result, the immune s...
...in shrinkage in social drinkers. Chronic heavy alc...Dr. Motoo Kubota and colleagues from Chiba Univers...al of Neurology, Neurosurgery & Psychiatry. Alcoho...physically and mentally, now turns out to potentia...
Other Medicine News:
(Date:11/19/2008)...udy did not achieve statistical significance , .../ -- Pharmos Corporation (Nasdaq: PARS ) today a...of its topical NanoEmulsion (NE) drug delivery tec...ne. , , The multi-center, randomized, doubl...safety and efficacy of the Company,s 3% Diclofenac...
(Date:11/19/2008)...illion Payment from Roche- , , MONTVALE, N....aceuticals Corp. (Nasdaq: MEMY ) today announced...Phase 2 trial of R3487/MEM 3454, its lead alpha-7 ...t associated with schizophrenia (CIAS). The Compa...l, triggering a $5.0 million payment from its part...
(Date:11/18/2008)..., Nov. 18 Forty-two lea...a November national forum to consider cutting-edge...th and national economy from outbreaks of dangerou...ay. , , Among those innovations: , , ...n kitchen table that detects highly contagious and...
(Date:11/13/2008)...Suggests Nutritional Supplements Prior to Surgery,...ewswire/ -- Identifying,malnutrition before surger...touring will significantly decrease surgical compl...uality and boost patient energy levels,according ...constructive,Surgery(R), the official medical jour...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 1Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 3650 4Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 1Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 2Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 3Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 4Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 1455 5DuraHeart 28TM 29 LVAS Receives Conditional Approval for US Pivotal Trial 1452 1DuraHeart 28TM 29 LVAS Receives Conditional Approval for US Pivotal Trial 1452 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 1Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 2Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 3Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 28DARA 29 1450 4
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution.
For the in vitro quantitative determination of glucose in human serum or plasma.
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent.
Medicine Products: